Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

被引：0

作者：

Ganesh Raghu

Mark J. Hamblin

A. Whitney Brown

Jeffrey A. Golden

Lawrence A. Ho

Marlies S. Wijsenbeek

Martina Vasakova

Alberto Pesci

Danielle E. Antin-Ozerkis

Keith C. Meyer

Michael Kreuter

Tracy Burgess

Nikhil Kamath

Francis Donaldson

Luca Richeldi

机构：

[1] University of Washington,Center for Interstitial Lung Diseases, Department of Medicine and Laboratory Medicine

[2] University of Kansas Medical Center,Pulmonary and Critical Care Medicine

[3] Inova Fairfax Hospital,Inova Advanced Lung Disease and Transplant Program

[4] University of California,Department of Medicine

[5] San Francisco,Department of Respiratory Medicine

[6] Erasmus MC,Department of Respiratory Medicine

[7] University Medical Center,School of Medicine and Surgery

[8] First Faculty of Medicine of Charles University and Thomayer Hospital,Pulmonary, Critical Care, and Sleep Medicine

[9] University of Milano-Bicocca,Department of Medicine, Division of Pulmonary and Critical Care

[10] ASST-Monza,Center for Interstitial and Rare Lung Diseases, Department of Pneumology

[11] Yale School of Medicine,undefined

[12] University of Wisconsin School of Medicine and Public Health,undefined

[13] Thoraxklinik,undefined

[14] University of Heidelberg and German Center for Lung Research,undefined

[15] Genentech,undefined

[16] Inc.,undefined

[17] Roche Products Ltd.,undefined

[18] Fondazione Policlinico Universitario A Gemelli IRCCS,undefined

[19] Università Cattolica del Sacro Cuore,undefined

来源：

Respiratory Research | / 23卷

关键词：

Recombinant human pentraxin-2 (rhPTX-2); Idiopathic pulmonary fibrosis (IPF); Long-term; Safety; Open-label extension; Forced vital capacity (FVC); 6-minute walk distance (6MWD);

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 109 条

[1]

Raghu G(2018)Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Am J Respir Crit Care Med 198 e44-e68

[2]

Remy-Jardin M(2018)Physiology of the lung in idiopathic pulmonary fibrosis Eur Respir Rev 27 59-S24

[3]

Myers JL(2019)The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry Respir Res 20 S17-2092

[4]

Richeldi L(2017)Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis J Manag Care Spec Pharm 23 1902279-2082

[5]

Ryerson CJ(2019)Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials BMJ Open Respir Res 6 2083-2307

[6]

Lederer DJ(2020)Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Eur Respir J 56 2071-664

[7]

Plantier L(2014)A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2299-824

[8]

Cazes A(2014)Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 1701209-21.e7

[9]

Dinh-Xuan AT(2018)Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial JAMA 319 657-162

[10]

Bancal C(2017)Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years Eur Respir J 50 788-1740

← 1 2 3 4 5 6 7 8 9 10 →